HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," - 801.HK; 910801.TW), China's leading integrated healthcare enterprise, today announced that the Group has continued to increase its ownership in its NYSE-listed affiliate, China Cord Blood Corporation ("CCBC," - CO.US) from the open market. As a result of which the Group now owns 40.9% of the issued share capital of CCBC from the previous 39.5%.
CCBC is the largest cord blood banking operator in China and is the only one with multiple exclusive licenses including Beijing Municipal, Guangdong Province and Zhejiang Province, with approximately 20% stake in the exclusive operator in Shandong Province.
Mr. Kam YUEN, Chairman and Chief Executive Officer of the Group, said, "We are proud to see that CCBC has sustained strong steady growth and profitability in its initial markets in Beijing and Guangdong while continuously deliver positive news on new market expansions since its initial public offering. As the founding and largest shareholder of CCBC, we remain optimistic of CCBC's prospects in both China and Asia Pacific and are duly confident in the capability of its management team. We see considerable room for CCBC to further enhance market penetration with steady growth and market development."
Under the "one-license-per-region" regulatory framework, the government has issued seven exclusive operating licenses thus far. The strategic coverage of CCBC's current operation in Beijing, Zhejiang and Guangdong has enabled it to capture key strategic economic strongholds in the affluent eastern coastline of China.
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China's leading integrated-healthcare devices and service operator, and the first medical device enterprise that was publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx) and the Taiwan Stock Exchange (TSE). Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets over the years, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.
Investor Relations Department
Golden Meditech Holdings Limited
Address: 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong
Tel: +852 3605 8180
Fax: +852 3605 8181
Email: ir@goldenmeditech.com